Biofrontera AG (BFFTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biofrontera AG (BFFTF) with AI Score 46/100 (Weak). Biofrontera AG is a biopharmaceutical company focused on dermatological products, particularly treatments for actinic keratoses. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Biofrontera AG (BFFTF) Healthcare & Pipeline Overview
Biofrontera AG, a German biopharmaceutical company, develops and markets dermatological products, primarily focusing on Ameluz for actinic keratoses treatment. Operating in the US, Europe, and Israel, Biofrontera distinguishes itself through its photodynamic therapy approach, facing competition from generic and specialty dermatology companies in a growing market for skin cancer treatments.
Investment Thesis
Biofrontera AG presents a speculative investment opportunity in the specialty dermatology market. The company's primary value driver is Ameluz, its photodynamic therapy treatment for actinic keratoses. Growth catalysts include expanding market penetration in the US and Europe, potential label expansions for Ameluz, and the development of new products like RhodoLED XL. However, Biofrontera's negative profit margin of -47.3% and reliance on a single key product represent significant risks. The company's small market capitalization of $0.02 billion and OTC listing also increase investment risk. Investors should carefully weigh the potential for growth against the financial challenges and competitive pressures facing Biofrontera.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion, indicating a micro-cap company with high growth potential but also higher risk.
- Gross margin of 66.0%, suggesting strong pricing power and efficient production of its dermatological products.
- Negative profit margin of -47.3%, highlighting the company's current challenges in achieving profitability despite strong gross margins.
- Beta of 0.59, indicating lower volatility compared to the overall market.
- The company's primary product, Ameluz, targets actinic keratoses, a growing market due to increasing awareness of sun damage and skin cancer prevention.
Competitors & Peers
Strengths
- Proprietary Ameluz formulation for actinic keratoses treatment.
- Established presence in key markets (US, Europe, Israel).
- Partnership with Maruho Co., Ltd.
Weaknesses
- Negative profit margin.
- High reliance on a single product (Ameluz).
- Small market capitalization and OTC listing.
Catalysts
- Upcoming: Clinical trial results for RhodoLED XL.
- Ongoing: Expansion of sales and marketing efforts in the US market.
- Ongoing: Pursuit of label expansion for Ameluz.
- Ongoing: Development of new dermatological products.
- Ongoing: Strategic partnerships and collaborations.
Risks
- Ongoing: Competition from established pharmaceutical companies and generic drug manufacturers.
- Potential: Regulatory hurdles and clinical trial failures.
- Potential: Product liability claims.
- Ongoing: Negative profit margin and financial challenges.
- Ongoing: Reliance on a single product (Ameluz).
Growth Opportunities
- Expansion in the United States Market: Biofrontera has the opportunity to further penetrate the US market for actinic keratoses treatments. The US represents a significant market due to its large population and high prevalence of sun exposure. By increasing its sales and marketing efforts, Biofrontera can capture a larger share of this market. The timeline for this growth opportunity is ongoing, with continuous efforts to expand market reach and increase brand awareness. Success in the US market could significantly boost Biofrontera's revenue and profitability.
- Development and Commercialization of RhodoLED XL: The development and commercialization of RhodoLED XL for the treatment of multiple interspersed lesions represents a significant growth opportunity for Biofrontera. This new product could expand the company's product portfolio and address a broader range of dermatological conditions. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approvals. If successful, RhodoLED XL could generate substantial revenue and contribute to Biofrontera's long-term growth.
- Geographic Expansion into New Markets: Biofrontera can pursue geographic expansion into new markets beyond its current focus on the United States, Europe, and Israel. Emerging markets with growing healthcare spending and increasing awareness of skin cancer prevention represent attractive opportunities. The timeline for this growth opportunity depends on market research, regulatory approvals, and the establishment of distribution networks. Successful geographic expansion could diversify Biofrontera's revenue streams and reduce its reliance on existing markets.
- Label Expansion for Ameluz: Biofrontera can pursue label expansion for Ameluz to include the treatment of other dermatological conditions beyond actinic keratoses. This could significantly increase the potential market for Ameluz and drive revenue growth. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approvals. Expanding the label for Ameluz would leverage the existing infrastructure and expertise of Biofrontera and maximize the value of its flagship product.
- Strategic Partnerships and Collaborations: Biofrontera can pursue strategic partnerships and collaborations with other pharmaceutical companies or healthcare providers to expand its reach and access new markets. Collaborations can provide access to new technologies, distribution channels, or funding. The timeline for this growth opportunity depends on identifying suitable partners and negotiating mutually beneficial agreements. Successful partnerships could accelerate Biofrontera's growth and enhance its competitive position.
Opportunities
- Expansion into new geographic markets.
- Label expansion for Ameluz to treat other skin conditions.
- Development and commercialization of new products like RhodoLED XL.
Threats
- Competition from established pharmaceutical companies and generic drug manufacturers.
- Regulatory hurdles and clinical trial risks.
- Potential for product liability claims.
Competitive Advantages
- Patented Ameluz formulation and photodynamic therapy approach.
- Established brand recognition in the actinic keratoses treatment market.
- Strategic partnership with Maruho Co., Ltd.
About BFFTF
Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera AG is a biopharmaceutical company specializing in the research, development, and commercialization of dermatological products. The company's flagship product is Ameluz, a topical prescription drug used in photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AK), a common precancerous skin condition caused by sun exposure. Ameluz is used in combination with Biofrontera's BF-RhodoLED lamp. Biofrontera's product portfolio also includes Belixos, an active cosmetic product designed for irritated and sensitive skin, and Xepi, a topical treatment for impetigo caused by antibiotic-resistant bacteria. The company is also developing RhodoLED XL for treating multiple interspersed lesions. Biofrontera markets its products primarily in the United States, Europe, and Israel, and has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera's strategic focus is on expanding the market for Ameluz and PDT, developing new dermatological products, and strengthening its presence in key geographic markets. The company competes with other pharmaceutical companies offering treatments for AK and other skin conditions, as well as with generic drug manufacturers. Biofrontera's commitment to innovation and its focus on PDT differentiate it from some of its competitors.
What They Do
- Researches and develops dermatological products.
- Markets and sells Ameluz for the treatment of actinic keratoses.
- Offers the BF-RhodoLED lamp for photodynamic therapy.
- Develops RhodoLED XL for treating multiple interspersed lesions.
- Provides Belixos, an active cosmetic product for sensitive skin.
- Offers Xepi for the treatment of antibiotic-resistant bacteria.
Business Model
- Develops and patents dermatological treatments.
- Manufactures and distributes its products directly and through partners.
- Generates revenue through product sales in the US, Europe, and Israel.
Industry Context
Biofrontera AG operates in the specialty dermatology segment of the pharmaceutical industry. This market is characterized by increasing demand for treatments for skin conditions such as actinic keratoses, driven by an aging population and rising awareness of sun damage. The competitive landscape includes established pharmaceutical companies, generic drug manufacturers, and other specialty dermatology companies. Biofrontera differentiates itself through its focus on photodynamic therapy with Ameluz. The global dermatology market is projected to continue growing, presenting opportunities for Biofrontera to expand its market share.
Key Customers
- Patients with actinic keratoses and other skin conditions.
- Dermatologists and other healthcare professionals.
- Hospitals and clinics offering dermatological treatments.
Financials
Chart & Info
Biofrontera AG (BFFTF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 10, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BFFTF.
Price Targets
Wall Street price target analysis for BFFTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BFFTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Pilar de la Huerta Martinez
Unknown
Information on Pilar de la Huerta Martinez's background is not available in the provided data. Without additional information, it is not possible to provide details on her career history, education, or previous roles.
Track Record: Information on Pilar de la Huerta Martinez's track record is not available in the provided data. Without additional information, it is not possible to provide details on key achievements, strategic decisions, or company milestones under her leadership.
BFFTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biofrontera AG may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited liquidity, price volatility, and information asymmetry.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and financial transparency.
- Higher bid-ask spreads and transaction costs.
- Increased risk of delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive landscape and market position.
- Evaluate the company's intellectual property and patent protection.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established business operations since 1997.
- Commercialization of dermatological products (Ameluz, Belixos, Xepi).
- Partnership with Maruho Co., Ltd.
- Operations in multiple countries (US, Europe, Israel).
- Focus on research and development of new dermatological treatments.
Common Questions About BFFTF
What does Biofrontera AG do?
Biofrontera AG is a biopharmaceutical company that specializes in the development and commercialization of dermatological products. Its primary product is Ameluz, a topical medication used in combination with the BF-RhodoLED lamp for photodynamic therapy (PDT) treatment of mild to moderate actinic keratoses. The company also offers other dermatological products like Belixos and Xepi, and is developing RhodoLED XL. Biofrontera operates primarily in the United States, Europe, and Israel, focusing on providing innovative solutions for skin conditions.
What do analysts say about BFFTF stock?
AI analysis is pending for BFFTF, so there is no current analyst consensus available. Key valuation metrics include a negative P/E ratio of -0.53 and a market capitalization of $0.02 billion. Growth considerations revolve around the successful commercialization of Ameluz and the development of new products. Investors should conduct their own due diligence and consider the risks associated with investing in a micro-cap OTC stock with limited analyst coverage.
What are the main risks for BFFTF?
The main risks for Biofrontera AG include its reliance on a single product (Ameluz), its negative profit margin, and its listing on the OTC market. Competition from established pharmaceutical companies and generic drug manufacturers poses a significant threat. Regulatory hurdles and the potential for clinical trial failures also represent risks. Investing in BFFTF carries additional risks associated with limited liquidity, price volatility, and the lack of regulatory oversight typical of OTC stocks.
What are the key factors to evaluate for BFFTF?
Biofrontera AG (BFFTF) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary Ameluz formulation for actinic keratoses treatment.. Primary risk to monitor: Ongoing: Competition from established pharmaceutical companies and generic drug manufacturers.. This is not financial advice.
How frequently does BFFTF data refresh on this page?
BFFTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BFFTF's recent stock price performance?
Recent price movement in Biofrontera AG (BFFTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Ameluz formulation for actinic keratoses treatment.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BFFTF overvalued or undervalued right now?
Determining whether Biofrontera AG (BFFTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BFFTF?
Before investing in Biofrontera AG (BFFTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stock investments carry higher risks than exchange-listed stocks.